Between 2020 and 2035, the North America Precision Diagnostics & Medicine market is projected to witness a robust increase in revenue. The market size, estimated at 17,800 Million USD in 2025, is expected to see CAGR of 8.1%, driven by ongoing technological advancements, broader application spectrum, and greater accessibility. Major contributors include investments in genomic sequencing, expansion of non-invasive tests, and improved reimbursement frameworks. The forecasting indicates sustained double-digit growth in the coming decade, with significant gains in both hospital and research laboratory channels.
Read More - https://bussinessinsights.com/research-report/north-america-precision-diagnostics-and-medicine-market
Oncology remains the largest application area for precision diagnostics and medicine in North America, accounting for a significant market share due to the high incidence of cancer and the critical need for precise, targeted therapies. Cardiology, neurology, and infectious diseases also represent substantial segments, fueled by innovation in non-invasive diagnostics and increased chronic disease prevalence. Companies are developing advanced tools for early detection and monitoring in these applications, reflecting a shift toward proactive, tailored care.
Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-precision-diagnostics-and-medicine-market
Who are the key players in North America Precision Diagnostics & Medicine Market industry?
The top 5 players are Thermo Fisher Scientific, Illumina Inc., Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers. These companies lead the market with innovative molecular diagnostics platforms, comprehensive genomic solutions, and personalized healthcare approaches, focusing on advancing precision medicine for cancer, genetic disorders, and chronic diseases throughout North America.
What is the North America Precision Diagnostics & Medicine Market growth?
The North America Precision Diagnostics & Medicine Market is experiencing robust growth, driven primarily by rapid advancements in genomic technologies and increased demand for personalized healthcare solutions. For example, Illumina reported significant sales growth in sequencing platforms in 2023, as healthcare providers prioritize tailored treatments across the region.
Which segment accounted for the largest North America Precision Diagnostics & Medicine Market share?
The oncology application segment holds the largest market share in North America’s Precision Diagnostics & Medicine sector. The surge in demand for early and precise cancer diagnostics, supported by platforms from companies like Roche Diagnostics, is facilitating targeted therapies and driving segment dominance in clinical practice.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com